Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6

Satoshi Ogasawara, Yuki Fujii, Mika K. Kaneko, Hiroharu Oki, Hemragul Sabit, Mitsutoshi Nakada, Hiroyoshi Suzuki, Koichi Ichimura, Takashi Komori, Yukinari Kato

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Gliomas are the most frequently occurring brain tumors with a heterogeneous molecular background. The molecular subgrouping of gliomas more prognostically stratifies patients into distinct groups compared with conventional histological classification. The most important molecules for the subtype diagnosis of diffuse gliomas are mutations of isocitrate dehydrogenase (IDH), TERT promoter, and α-thalassemia/mental-retardation-syndrome-X-linked (ATRX) and the codeletion of 1p/19q. Among them, IDH and ATRX mutations can be diagnosed using specific monoclonal antibodies (mAbs). We have developed many mAbs against IDH mutants, including HMab-1/HMab-2 against IDH1-R132H and multispecific mAbs MsMab-1/MsMab-2 against IDH1/2 mutations. In contrast, highly sensitive mAbs against ATRX remain to be established. In this study, we immunized mice with recombinant human ATRX and developed a novel mAb, AMab-6. The dissociation constant of AMab-6 was determined to be 9.7 × 10-10 M, indicating that the binding affinity of AMab-6 is very high. Furthermore, AMab-6 sensitively detects ATRX in Western blot and immunohistochemical analyses, indicating that AMab-6 could become the standard marker to determine the ATRX mutation status of gliomas in immunohistochemical analyses.

Original languageEnglish
Pages (from-to)254-258
Number of pages5
JournalMonoclonal Antibodies in Immunodiagnosis and Immunotherapy
Issue number5
Publication statusPublished - 2016 Oct


  • ATRX
  • glioma
  • immunohistochemistry


Dive into the research topics of 'Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6'. Together they form a unique fingerprint.

Cite this